Department of Microbiology, Ajou University School of Medicine, Suwon 16499, Republic of Korea.
Department of Biomedical Sciences, Ajou University School of Medicine, Suwon 16499, Republic of Korea.
Int J Mol Sci. 2024 Aug 6;25(16):8571. doi: 10.3390/ijms25168571.
Ulcerative colitis (UC) is a persistent inflammatory intestinal disease that consistently affects the colon and rectum. Its exact cause remains unknown. UC causes a considerable challenge in healthcare, prompting research for novel therapeutic strategies. Although probiotics have gained popularity as possible candidates for managing UC, studies are still ongoing to identify the best probiotics or probiotic mixtures for clinical applications. This study aimed to determine the efficacy of a multi-strain probiotic mixture in mitigating intestinal inflammation in a colitis mouse model induced by dextran sulfate sodium. Specifically, a multi-strain probiotic mixture consisting of and was used to study its impact on colitis symptoms. Anti-inflammatory effects were evaluated using ELISA and flow cytometry. The configuration of gut microbial communities was determined using 16S rRNA metagenomic analysis. According to this study, colitis mice treated with the probiotic mixture experienced reduced weight loss and significantly less colonic shortening compared to untreated mice. Additionally, the treated mice exhibited increased levels of forkhead box P3 (Foxp3) and interleukin 10, along with decreased expression of dendritic cell activation markers, such as CD40+, CD80+, and CD83+, in peripheral blood leukocytes and intraepithelial lymphocytes. Furthermore, there was a significant decrease in the frequencies of CD8+N.K1.1+ cells and CD11b+Ly6G+ cells. In terms of the gut microbiota, probiotic-mixture treatment of colitis mice significantly increased the abundance of the phyla and ( < 0.05). These results provide valuable insights into the therapeutic promise of multi-strain probiotics, shedding light on their potential to alleviate colitis symptoms. This research contributes to the ongoing exploration of effective probiotic interventions for managing inflammatory bowel disease.
溃疡性结肠炎（UC）是一种持续性炎症性肠病，持续影响结肠和直肠。其确切原因尚不清楚。UC 在医疗保健方面带来了巨大挑战，促使人们研究新的治疗策略。虽然益生菌已作为治疗 UC 的可能候选药物受到关注，但仍在进行研究以确定最佳的益生菌或益生菌混合物用于临床应用。本研究旨在确定一种多菌株益生菌混合物在减轻葡聚糖硫酸钠诱导的结肠炎小鼠模型肠道炎症中的功效。具体来说，使用由 和 组成的多菌株益生菌混合物来研究其对结肠炎症状的影响。使用 ELISA 和流式细胞术评估抗炎作用。通过 16S rRNA 宏基因组分析确定肠道微生物群落的结构。根据这项研究，用益生菌混合物治疗的结肠炎小鼠与未治疗的小鼠相比，体重减轻减少，结肠缩短明显减少。此外，治疗小鼠的外周血白细胞和上皮内淋巴细胞中叉头框 P3（Foxp3）和白细胞介素 10 的水平升高，而树突状细胞活化标志物如 CD40+、CD80+和 CD83+的表达降低。此外，CD8+N.K1.1+细胞和 CD11b+Ly6G+细胞的频率显著降低。就肠道微生物群而言，益生菌混合物治疗结肠炎小鼠显著增加了门 和 的丰度（<0.05）。这些结果为多菌株益生菌的治疗潜力提供了有价值的见解，表明它们有可能缓解结肠炎症状。这项研究为管理炎症性肠病的有效益生菌干预措施的持续探索做出了贡献。
